SCHEMBL1817023

SCHEMBL1817023

C#CC(O)(c1cc(OC)cc(OC)c1)c1cc(OC)cc(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
CYP1A1 P04798 3/20 0.37
CYP1B1 Q16678 3/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CYP3A4 P08684 2/20 0.35
ABL1 P00519 2/20 0.35
ABCB1 P08183 2/20 0.35
BCR P11274 2/20 0.35
ELANE P08246 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2E1 P05181 1/20 0.33
CYP2C8 P10632 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11914194 0.91 ALDH1A1 (0.38) ALDH1A1KDM4EGAACYP1A1CYP1B1
SCHEMBL2491707 0.89 PDE4A (0.40) ALDH1A1KDM4ECYP1A1CYP1B1CYP3A4
SCHEMBL15171996 0.89 CYP3A4 (0.35) ALDH1A1KDM4EGAACA1CA2
SCHEMBL15171999 0.81 ACHE (0.36) ALDH1A1KDM4ECYP3A4PDE4APDE4B
SCHEMBL15172001 0.81 ACHE (0.36) ALDH1A1KDM4ECYP3A4PDE4APDE4B
SCHEMBL25954061 0.79 ELANE (0.46) ALDH1A1CA1CA2ELANESMN1; SMN2
SCHEMBL164160 0.79 ELANE (0.46) ALDH1A1CA1CA2ELANESMN1; SMN2
SCHEMBL8131087 0.77 KIF11 (0.44) ALDH1A1CA1CA2CYP3A4SMN1; SMN2
SCHEMBL30730699 0.76 CYP3A4 (0.47) ALDH1A1KDM4EGAACYP1A1CYP1B1
SCHEMBL25489581 0.75 ALDH1A1 (0.58) ALDH1A1KDM4EGAACYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170022232-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS SCHRODI YANN (US) 2017-01-26 US disclosed
US-9273081-B2 Method for in-situ formation of metathesis catalysts ExxonMobil Product Solutions Company 2016-03-01 US disclosed
US-20150299235-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS ExxonMobil Product Solutions Company 2015-10-22 US disclosed
EP-2866936-A1 METATHESIS CATALYST AND PROCESS FOR USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2015-05-06 EP disclosed
US-8809563-B2 Metathesis catalyst and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-08-19 US disclosed
US-8809563-B2 Metathesis catalyst and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-08-19 US disclosed
WO-2014004089-A1 METATHESIS CATALYST AND PROCESS FOR USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-01-03 WO disclosed
US-20130204026-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS MATERIA, INC. (US) 2013-08-08 US disclosed
EP-2533899-A2 METATHESIS CATALYST AND PROCESS FOR USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-12-19 EP disclosed
US-20120289729-A1 Metathesis Catalyst and Process for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2012-11-15 US disclosed
US-20120289729-A1 Metathesis Catalyst and Process for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2012-11-15 US disclosed
US-8237003-B2 Metathesis catalyst and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-08-07 US disclosed
US-8237003-B2 Metathesis catalyst and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-08-07 US disclosed
WO-2011100022-A2 METATHESIS CATALYST AND PROCESS FOR USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-18 WO disclosed
WO-2011100022-A2 METATHESIS CATALYST AND PROCESS FOR USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-18 WO disclosed
US-20110112349-A1 Metathesis Catalyst and Process for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-05-12 US disclosed
US-20110112349-A1 Metathesis Catalyst and Process for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299235-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS CHRM1, ACSL1, LOXL1 ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885
US-20170022232-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS CHRM1, ACSL1, LOXL1 ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885
US-20120289729-A1 Metathesis Catalyst and Process for Use Thereof MGLL, FASN, FDFT1 ALDH1A1 2327/4885KDM4E 1887/4885GAA 844/4885
US-20130204026-A1 METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS CHRM1, ACSL1, LOXL1 ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885
US-20110112349-A1 Metathesis Catalyst and Process for Use Thereof MGLL, FASN, MSMO1 ALDH1A1 1338/4885KDM4E 2254/4885GAA 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.